Letter by Imprialos et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"

Circulation. 2016 Jul 12;134(2):e5-6. doi: 10.1161/CIRCULATIONAHA.116.022220.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / drug therapy*
  • Factor Xa Inhibitors / therapeutic use
  • Hemorrhage / drug therapy
  • Humans
  • Morpholines / therapeutic use
  • Polypharmacy
  • Rivaroxaban
  • Stroke / drug therapy
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Morpholines
  • Warfarin
  • Rivaroxaban